(TRIL), Quotes and News Summary

TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.

Earnings

see more
Q3 2022Est.ActualSurprise
EPS
(EXPECTED)2022-11-11
REV
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-30
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target